Potassium News and Research

RSS

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Taking dietary supplements for adrenal fatigue may do more harm than good

Taking vitamins or supplements to treat "adrenal fatigue" may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

18 Mar 2010

Positive results from Phase IIa epilepsy study of ICA-105665

Icagen, Inc. today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.

16 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.

11 Mar 2010

Review suggests ion exchange resins are not effective for hyperkalemia

For more than half a century, products containing ion exchange resins have been used in patients with dangerously high levels of potassium. However, there is no convincing evidence that these products are actually effective, according to an article appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

10 Mar 2010

Teens who drink 100% fruit juice have lower intakes of dietary fat and higher intakes of nutrients

New research published in the March/April issue of the American Journal of Health Promotion shows that teens who drink 100 percent fruit juice have more nutritious diets overall compared to non-consumers.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

2 Mar 2010

Study reveals most consumers are unclear about dietary nutrients

When it comes to dietary nutrients, most consumers don't know the whole story. A recent study by the Innovation Center for U.S. Dairy revealed that the fact that milk delivers much more than calcium to the diet is new "news" to consumers.

2 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

Creators of Milk Mustache "got milk?" Campaign toast Let's Move! program

The creators of the popular Milk Mustache "got milk?" Campaign are toasting the new Let's Move! initiative that was unveiled by First Lady Michelle Obama. Instead of the latest celebrity sporting a white upper lip, the new ad features children – who have the most to gain from the new Let's Move! program, which aims to solve the childhood obesity problem in a generation.

26 Feb 2010

Avoiding dairy products due to lactose intolerance may pose diet and health risks, say experts

People may avoid milk and other dairy products due to concerns about lactose intolerance, but eliminating these nutrient-rich foods may not only be unnecessary to manage the condition - it could impact diet and health, concludes a panel of experts assembled by the National Institutes of Health (NIH).

26 Feb 2010

Soy products meet nutritional needs of people with lactose intolerance

Today, nutrition experts and physicians who participated in the NIH Consensus Development Conference on Lactose Intolerance and Health released an important report that concluded individuals who ingest inadequate amounts of calcium and vitamin D because of real or perceived lactose intolerance need dietary advice to ensure appropriate intake of missing nutrients.

25 Feb 2010

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Watson Pharmaceuticals, Inc. today reported net revenue for the fourth quarter ended December 31, 2009 climbed 22 percent to $785.7 million, compared to $645.2 million in the fourth quarter 2008.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Committee calls for strategies to curb hypertension

Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.

23 Feb 2010

New gene locus influencing risk for atrial fibrillation identified

Atrial fibrillation is a cardiac arrhythmia - a chronic irregularity of heartbeat - which affects an estimated 1 million people in Germany. Although the condition is not acutely life-threatening, it does increase the risk of developing more serious illnesses, such as cardiac insufficiency, stroke and dementia. In the third of a series of genomewide asssociation studies, an international team of researchers, led by LMU physician PD Dr. Stefan K--b, now reports the identification of a new gene locus that has a significant influence on risk for atrial fibrillation.

22 Feb 2010

Potassium News and Research

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Taking dietary supplements for adrenal fatigue may do more harm than good

Positive results from Phase IIa epilepsy study of ICA-105665

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

Review suggests ion exchange resins are not effective for hyperkalemia

Teens who drink 100% fruit juice have lower intakes of dietary fat and higher intakes of nutrients

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Study reveals most consumers are unclear about dietary nutrients

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Creators of Milk Mustache "got milk?" Campaign toast Let's Move! program

Avoiding dairy products due to lactose intolerance may pose diet and health risks, say experts

Soy products meet nutritional needs of people with lactose intolerance

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Committee calls for strategies to curb hypertension

New gene locus influencing risk for atrial fibrillation identified

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News